Design, Development and Evaluation Of Anti-Hypertensive Drug Solid Lipid Nano Particles

American Journal of PharmTech Research Pub Date : 2021-08-07 DOI:10.46624/ajptr.2021.v11.i4.006

R. Chethan, P. Ashokkumar

{"title":"Design, Development and Evaluation Of Anti-Hypertensive Drug Solid Lipid Nano Particles","authors":"R. Chethan, P. Ashokkumar","doi":"10.46624/ajptr.2021.v11.i4.006","DOIUrl":null,"url":null,"abstract":"Recently, solid lipid Nano-particles have received much attention by the researchers owing to \nits biodegradability, biocompatibility and the ability to deliver a wide range of drugs. The aim of \nthe present study was to design Diltiazem solid lipid Nano-particles and to evaluate them. \nDiltiazem solid lipid Nano-particles were prepared by hot homogenization technique using \ndifferent lipids (Tristearin, GMS and Comprital), soy lecithin as stabilizers and tween \n80, Poloxamer as surfactants. The Nano-particles were evaluated for particle size & PDI, zeta \npotential, entrapment efficiency and in vitro drug release. The particle size ranged from 49.7 to \n523.7 nm. PDI of all formulations were good within the range of 0.189 to 0.427. The zeta \npotential ranged from -10.5 to -29.6 Mv, Entrapment efficiency of all formulations were \nobserved was in the range of 78.68 to 95.23 %. The cumulative percentage release of Diltiazem \nfrom different Diltiazem Nano-particles varied from 53.36 to 88.74% depending upon the drug \nlipid ratio and the type of lipid used. The average percentage of drug released from different \nSLNs after 24 hours showed in the following order: F9 (53.35%) < F6 (56.75%) < F4 (61.74%) < \nF7 (63.8%) < F5(67.77%) < F8(69.04%) < F3(75.31%) < F1(79.36%) <F2 (88.74%) \nrespectively. The release kinetic studies showed that the release was first order diffusion controlled \nand the n values obtained from the Korsmeyer-Peppa’s model indicated the release mechanism \nwas Quasi-Fickian type (n-value of 0.47). \nKeywords: Diltiazem, solid lipid Nano-particles, FTIR, in vitro drug release.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"21 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of PharmTech Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46624/ajptr.2021.v11.i4.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, solid lipid Nano-particles have received much attention by the researchers owing to its biodegradability, biocompatibility and the ability to deliver a wide range of drugs. The aim of the present study was to design Diltiazem solid lipid Nano-particles and to evaluate them. Diltiazem solid lipid Nano-particles were prepared by hot homogenization technique using different lipids (Tristearin, GMS and Comprital), soy lecithin as stabilizers and tween 80, Poloxamer as surfactants. The Nano-particles were evaluated for particle size & PDI, zeta potential, entrapment efficiency and in vitro drug release. The particle size ranged from 49.7 to 523.7 nm. PDI of all formulations were good within the range of 0.189 to 0.427. The zeta potential ranged from -10.5 to -29.6 Mv, Entrapment efficiency of all formulations were observed was in the range of 78.68 to 95.23 %. The cumulative percentage release of Diltiazem from different Diltiazem Nano-particles varied from 53.36 to 88.74% depending upon the drug lipid ratio and the type of lipid used. The average percentage of drug released from different SLNs after 24 hours showed in the following order: F9 (53.35%) < F6 (56.75%) < F4 (61.74%) < F7 (63.8%) < F5(67.77%) < F8(69.04%) < F3(75.31%) < F1(79.36%)

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗高血压药物固体脂质纳米颗粒的设计、研制与评价

近年来，固体脂质纳米颗粒因其生物可降解性、生物相容性和广泛的药物递送能力而受到研究人员的广泛关注。本研究的目的是设计地尔硫卓固体脂质纳米颗粒并对其进行评价。采用热均质技术，以不同脂质(Tristearin、GMS和Comprital)、大豆卵磷脂为稳定剂、tween 80、poloxomer为表面活性剂制备了地尔硫卓固体脂质纳米颗粒。对纳米颗粒的粒径、PDI、zeta电位、包封效率和体外药物释放度进行了评价。粒径范围为49.7 ~ 523.7 nm。各配方的PDI在0.189 ~ 0.427范围内均较好。zeta电位范围为-10.5 ~ -29.6 Mv，包封率为78.68% ~ 95.23%。不同的地尔硫卓纳米颗粒对地尔硫卓的累积释放百分比根据药物脂质比和所使用的脂质类型而变化，从53.36%到88.74%不等。24 h后不同sln的平均释药率依次为:F9 (53.35%) < F6 (56.75%) < F4 (61.74%) < F7 (63.8%) < F5(67.77%) < F8(69.04%) < F3(75.31%) < F1(79.36%)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American Journal of PharmTech Research

自引率

0.00%

发文量